Internal Medicine, Rheumatology · Tuscaloosa, AL
NPI
1720215049
Since 2009
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
100 Towncenter Blvd, Suite 112
Tuscaloosa, AL, 35406
Phone (205) 750-0030
Groups this clinician bills Medicare through
Medicare paid, 2024
$982K
219,897 services
Medicare patients, 2024
528
Average age 72
Drug cost, 2024
$12.9M
7,329 prescriptions
Company payments, 2025
$103K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ray H McLaughlin Jr. was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 196,401 times for 54 patients. In total Ray H McLaughlin Jr. billed 219,897 services in 70 codes, and Medicare paid $982K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-11-25.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 196,401 | 54 | $3.61 | $710K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 10,430 | 143 | $0.10 | $1,034 |
| J0897 Injection, denosumab, 1 mg | Office | 6,840 | 71 | $20.64 | $141K |
| 96372 Injection Administration | Office | 745 | 137 | $9.74 | $7,257 |
| 99214 Office E&M - Established | Office | 694 | 399 | $79.41 | $55K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 549 | 381 | $11.41 | $6,262 |
| 86140 Clinical Chemistry | Office | 548 | 353 | $5.06 | $2,771 |
| 85652 Clinical Chemistry | Office | 546 | 350 | $2.64 | $1,440 |
| 85025 Blood Count | Office | 516 | 328 | $7.56 | $3,903 |
| 80053 Clinical Chemistry | Office | 512 | 326 | $10.27 | $5,261 |
| 36415 Venipuncture Blood Collection | Office | 510 | 329 | $8.65 | $4,412 |
| 73130 X-ray - Upper Extremity | Office | 118 | 59 | $18.78 | $2,216 |
| 86431 Immunoassay | Office | 113 | 113 | $5.55 | $628 |
| 86160 Immunoassay | Office | 112 | 54 | $11.49 | $1,287 |
| 20610 Joint Injection | Office | 109 | 81 | $45.09 | $4,915 |
By year: 2022 $824K for 143,387 services; 2023 $877K for 175,894 services; 2024 $982K for 219,897 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 86140 Clinical Chemistry | 548 | 353 | $5.06 | $2,771 |
| 85652 Clinical Chemistry | 546 | 350 | $2.64 | $1,440 |
| 85025 Blood Count | 516 | 328 | $7.56 | $3,903 |
| 80053 Clinical Chemistry | 512 | 326 | $10.27 | $5,261 |
| 36415 Venipuncture Blood Collection | 510 | 329 | $8.65 | $4,412 |
| 86431 Immunoassay | 113 | 113 | $5.55 | $628 |
| 86160 Immunoassay | 112 | 54 | $11.49 | $1,287 |
| 84550 Clinical Chemistry | 53 | 45 | $4.43 | $235 |
| 82306 Clinical Chemistry | 34 | 34 | $29.01 | $986 |
| 82550 Clinical Chemistry | 30 | 25 | $6.38 | $191 |
Medicare prescription drug claims, 2024
In 2024, the drug Ray H McLaughlin Jr. prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,589 prescriptions and refills. In total Ray H McLaughlin Jr. wrote 7,329 Medicare prescriptions that cost $12.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,589 | 4,439 | 550 | $109K |
| Prednisone Generic | 762 | 1,384 | 358 | $4,438 |
| Methotrexate Methotrexate Sodium | 495 | 1,128 | 152 | $12K |
| Kevzara Sarilumab | 410 | 410 | 50 | $1.7M |
| Allopurinol Generic | 266 | 724 | 78 | $3,295 |
| Rinvoq Upadacitinib | 265 | 285 | 36 | $1.8M |
| Humira(Cf) Pen Adalimumab | 248 | 259 | 32 | $2.1M |
| Duloxetine Hcl Generic | 189 | 481 | 58 | $4,857 |
| Enbrel Sureclick Etanercept | 186 | 190 | 24 | $1.4M |
| Tramadol Hcl Generic | 181 | 189 | 49 | $1,204 |
| Orencia Clickject Abatacept | 177 | 181 | 17 | $992K |
| Alendronate Sodium Generic | 174 | 488 | 68 | $1,784 |
| Leflunomide Generic | 135 | 316 | 42 | $12K |
| Xeljanz Xr Tofacitinib Citrate | 135 | 139 | 14 | $773K |
| Gabapentin Generic | 110 | 293 | 51 | $2,604 |
Brand drugs: 2,237 claims; generic drugs: 5,058 claims; opioid claims: 293.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ray H McLaughlin Jr. $103K ($103K in general payments such as food, travel and fees) from 16 companies. The largest payer was UCB, Inc. with $32K.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 51 | $32K |
| Abbvie Inc. ABBV | 41 | $27K |
| Amgen Inc. AMGN | 56 | $22K |
| Genzyme Corporation SNY | 25 | $19K |
| Sobi, Inc SOBI.ST | 4 | $2,440 |
| GlaxoSmithKline, LLC. GSK | 13 | $390 |
| Janssen Biotech, Inc. JNJ | 7 | $223 |
| Radius Health, Inc. | 12 | $195 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $189 |
| Alnylam Pharmaceuticals Inc. ALNY | 1 | $120 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.